CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 600 enrolled
Drug / intervention
Ethinyl Estradiol / Norgestimate Oral Tabletdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04828824
NCT04828824Phase 4Completed
CompareCT.gov

Reduction of Premature Discontinuation of Contraceptive Implants by Advance Provision of an OCP-based Participant Intervention: Randomized Clinical Trial

University of Colorado, Denver·interventional·Posted Apr 2, 2021·Updated Apr 23, 2026

In Brief

A Phase 4 clinical trial evaluating Ethinyl Estradiol / Norgestimate Oral Tablet for Contraception Behavior. Completed, enrolled 600 participants across 1 site.

Detailed Summary

To compare rates of etonogestrel implant discontinuation in implant initiators who are given advance provision of combined oral contraceptive pills (COCs) and a bleeding rescue regimen (COCR intervention) to participants given standard counseling (comparator).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsContraception Behavior
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
20222023202420252026
First PostedApr 2, 2021
Enrollment StartJun 18, 2021
Primary CompletionNov 12, 2025
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 5.3 years ago

Interventions

Ethinyl Estradiol / Norgestimate Oral Tabletdrug

Those who desire COCs as an intervention are prescribed (over the phone) or given (in person) 3 packs of COCs. They are told to take one pill per day until the first pack is complete and save the remaining 2 packs for possible future use.